BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
